New drug approval addresses two cardiovascular risk factors
Daiichi Sankyo's Welchol, formerly approved to lower LDL-C, has been cleared to reduce blood glucose levels in Type 2 diabetics
Daiichi Sankyo's Welchol (colesevelam HCl) has gained approval for a new indication. It can be used to reduce AIC in adults with Type 2 diabetes. The bile acid sequestrant was approved in 2000 alone or in combination with a statin to reduce elevated LDL-C in patients with primary hypercholesterolemia. The Parsippany, N.J., firm claims the product is the first and only medication approved to lower both glucose levels and low-density lipoprotein cholesterol.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
